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SUMMARY
The impact of di-cationic pentamidine-analogues against Toxoplama gondii (Rh- and Me49-background) was investigated.
The 72 h-growth assays showed that the arylimidamide DB750 inhibited the proliferation of tachyzoites ofT. gondii Rh and
T. gondii Me49with an IC50 of 0·11 and 0·13 μM, respectively. Pre-incubation of ﬁbroblast monolayers with 1 μMDB750 for
12 h and subsequent culture in the absence of the drug also resulted in a pronounced inhibiton of parasite proliferation.
However, upon 5–6 days of drug exposure,T. gondii tachyzoites adapted to the compound and resumed proliferation up to a
concentration of 1·2 μM. Out of a set of 32 di-cationic compounds screened for in vitro activity against T. gondii, the
arylimidamideDB745, exhibiting an IC50 of 0·03 μM and favourable selective toxicity was chosen for further studies.DB745
also inhibited the proliferation of DB750-adapted T. gondii (IC50=0·07 μM). In contrast to DB750, DB745 also had a
profound negative impact on extracellular non-adapted T. gondii tachyzoites, but not on DB750-adapted T. gondii.
Adaptation ofT. gondii toDB745 (up to a concentration of 0·46 μM)wasmuchmore diﬃcult to achieve and feasible only over
a period of 110 days. In cultures infected with DB750-adapted T. gondii seemingly intact parasites could occasionally be
detected by TEM. This illustrates the astonishing capacity of T. gondii tachyzoites to adapt to environmental changes, at
least under in vitro conditions, and suggests that DB745 could be an interesting drug candidate for further assessments in
appropriate in vivo models.
Key words: Toxoplasma gondii, di-cationic pentamidine analogues, arylimidamides, proliferation, tachyzoites, in vitro
models.
INTRODUCTION
The obligatory intracellular apicomplexan parasite
Toxoplasma gondii is one of the most successful para-
sites on this planet. It infects members of Felidae as
deﬁnitive hosts, and has a wide range of intermediate
hosts, including warm-blooded animals and humans
(Tenter et al. 2000; Dabritz and Conrads, 2010).
Approximately one third of the human population is
infected with T. gondii worldwide, but despite the
high prevalence, in the vast majority of cases disease
is benign and asymptomatic (Barratt et al. 2010).
However, clinical problems can arise in 2 situations.
First, in individuals with an immature immune sys-
tem or in immune-compromised patients infection
can lead to toxoplasmic encephalitis (TE) or even
death.TEoccurs as a result of the reactivation of brain
cysts that encapsulate slowly proliferating brady-
zoites, which then undergo bradyzoite-to-tachyzoite
stage conversion, and is common in chronically
infected patients, which receive immunosuppressive
therapy or suﬀer from human immunodeﬁciency
virus (HIV) infection (Tenter et al. 2000; Barratt et al.
2010; Henriquez et al. 2010). Secondly, congenital
toxoplasmosis poses amajor health risk upon primary
maternal infection during pregnancy, leading to
placental or fetal infection (or both), which often
results in abortion or damage of the fetal tissues
(Feldman et al. 2010). In addition, T. gondii is also a
highly signiﬁcant economic and veterinary medical
concern in the livestock industry, and as such rep-
resents an important zoonosis (Dubey, 2009).
Toxoplasmosisbeginsgenerallymildlyor is asymp-
tomatic, with an acute phase in which tachyzoites
invade the cells, divide rapidly, and disseminate
throughout the host. With the onset of the host im-
mune response, the proliferative tachyzoite stage is
replaced by the quiescent bradyzoites, which form
tissue cysts predominantly located in the central
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nervous system (CNS) and muscle tissue, where they
do not cause apparent immunopathology and can
persist for many years, up to a lifetime ( Carruthers
and Suzuki, 2007; Laliberté and Carruthers, 2008).
The chemotherapeutical options for the treatment
of toxoplasmosis are limited. A synergistic combi-
nation therapy comprised of sulfadiazine and pyri-
methamine, targeting the synthesis and the reduction
of folic acid in tachyzoites, has been shown to be
the most eﬃcient option (Montoya and Liesenfeld,
2004). However, adverse reactions can occur,
which include haematological toxicity and hyper-
sensitivity. Another option employs clindamycin-
pyrimethamine combination therapy, but this
treatment is also prone to side eﬀects (Pereira-
Chioccola et al. 2009). The major problem in the
treatment of T. gondii infection is the non-eﬀective-
ness of compounds against bradyzoites that are
enclosed in tissue cysts (Barratt et al. 2010).
Pentamidine and its analogues represent a class
of broad-spectrum antimicrobial compounds, with
activities against a wide range of intracellular and
extracellular protozoan parasites (Soeiro et al. 2005;
Wilson et al. 2008; Buckner andNavabi, 2010). Since
its discovery, pentamidine has been successfully
applied to treat African trypanosomiasis, leishma-
niasis, and malaria in humans, and the pentamidine-
derivative diminazene aceturate is commonly
used for trypanosome chemotherapy in livestock
(Werbovetz, 2006). More recently, novel analogues,
known as arylimidamides, with a more favourable
pharmacokinetic proﬁle, improved bioavailability
and lower host toxicity were shown to be eﬀective
against Leishmania donovani and Trypanosoma cruzi
in vitro and in vivo (Wang et al. 2010; Batista et al.
2010a).
The in vitro eﬃcacy of pentamidine and some
pentamidine analogues against T. gondii has been
demonstrated previously (Lindsay et al. 1991), and
proliferation inhibitory properties were reported at
concentrations of around 10 μg/ml. More recently,
Leepin et al. (2008) demonstrated the in vitro eﬃcacy
of a set of arylimidamides (DB750, DB766, DB786,
DB811, formerly named reversed diamidines), which
inhibited the proliferation ofT. gondii and the closely
related Neospora caninum with IC50s at submicro-
molar concentrations ranging between 0·16 and
0·66 μM (=0·14–0·5 μg/ml), indicating the potential
of these di-cationic compounds, especially DB750
and DB786, for chemotherapeutical purposes.
DB811 was recently reported to inhibit the prolifer-
ation of the related apicomplexanBesnoitia besnoiti in
Vero cells at an IC50 of 0·08 μM (Cortes et al. 2011).
Here, we further explore the in vitro characteristics
of DB750 in relation to T. gondii. We demonstrate
that, despite low IC50 in 3-day growth assays, Toxo-
plasma tachyzoites could readily adapt to this com-
pound during culture within a few days, while this
was not possible for the closely related N. caninum.
Screening of additonal di-cationic compounds for
anti-Toxoplasma activity lead to the identiﬁcation of
DB745, which inhibited the proliferation ofT. gondii
tachyzoites at an IC50 of 0·03 μM. Also, the eﬀects of
DB745 and DB750 were evaluated by transmission
electron microscopy analysis of DB750-adapted and
non-adapted T. gondii parasites.
MATERIALS AND METHODS
Culture media, buﬀers and reagents
Unless otherwise stated, all tissue-culturemedia were
purchased from Gibco-BRL (Zurich, Switzerland)
and biochemical reagents were fromSigma (St Louis,
MO, USA). The di-cationic compounds used in
this study were synthesized at the Department of
Chemistry and Center for Biotechnology and Drug
Design, Georgia State University, USA. They were
kept as a dry powder or as stock solutions of 1 mg/ml
in dimethyl sulfoxide and were stored at −20 °C.
Cell culture and parasite puriﬁcation
Vero cells were maintained in RPMI 1640 medium
supplemented with 5% fetal calf serum (FCS), 2 mM
L-glutamine, 50U of penicillin/ml, and 50 μg of
streptomycin/ml at 37 °C with 5% CO2 in tissue-
culture ﬂasks and were trypsinized 3 times a week.
Human foreskin ﬁbroblasts (HFF) were maintained
in Dulbecco’s modiﬁed Eagles’s medium (DMEM)
with 10% FCS, 50U of penicillin/ml, and 50 μg
of streptomycin/ml at 37 °C with 5% CO2 in tissue-
culture ﬂasks. Cultures were trypsinized once a week.
Toxoplasma gondii Me49, T. gondii Rh, T. gondii-
β-gal, (a transgenic strain with Rh-background
expressing β-galactosidase; McFadden et al. 1997)
were cultured in Vero cells (Scheidegger et al. 2005).
Intracellular parasites were harvested by trypsiniza-
tion of infected Vero cells, followed by repeated
passages through a 25-gauge needle at 4 °C, and sep-
aration from cell debris on a Sephadex-G25 column
as described previously (Hemphill, 1996). Puriﬁed
tachyzoites were used to infect HFF monolayers as
described below.
In vitro drug treatment assays employing T. gondii
Me49 and DB750-adapted T. gondii_DB750 by
quantitative real time PCR
HFF cells were grown to conﬂuency in 24-well
tissue-culture plates, either adherent to glass cover-
slips or directly on the plastic surface. Each well was
infected with 5×104 cell culture-derived and freshly
puriﬁed T. gondii tachyzoites re-suspended in
DMEM containing 5% FCS, 50U of penicillin/ml,
and 50 μg of streptomycin/ml (=full medium).
Following incubation for 1 h at 37 °C in a 5% CO2
athmosphere, unbound parasites were removed by
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washing in DMEM, and 1ml of full medium was
added, containing the compounds at concentrations
as indicated in the individual experiments. In some
experiments, DB750 (1 μM) was added to parasites
and/or host cells already prior to infection, as indi-
cated below. For a list of some of these compounds
refer to Table 1. Each experiment included controls
such as (i) parasite-infected HFF in full medium
containing respective concentrations of the DMSO-
solvent and (ii) uninfected HFF monolayers in drug-
containing full medium to assess selective toxicity.
The cultures were maintained at 37 °C in a 5% CO2
atmosphere during diﬀerent periods of time as indi-
cated below, and were inspected daily by light
microscopy. Samples for quantitative real time PCR
analysis were taken by removal of the medium and
addition of a mixture of 200 μl of phosphate-buﬀered
saline (PBS), 180 μl of lysis buﬀer and 20 μl of
proteinase K (DNAeasy Kit, QIAGEN, Basel,
Switzerland). Samples were stored at −20 °C until
further analysis was carried out. The quantiﬁcation of
parasites was done by qPCR according to previously
described protocols (Costa et al. 2000; Scheidegger
et al. 2005). As external standards, samples contain-
ing the DNA from 0, 10, 100, and 1000 T. gondii
tachyzoites were included. The parasite numbers in
the experimental samples were deduced by interp-
olation from the standard curve.
In vitro drug treatment assays employing
T. gondii β-gal
These assays were done essentially as previously
described (Müller et al. 2009). HFFmonolayers were
grown to conﬂuency in 96-well ﬂat-bottommed
microtitre plates. For each assay, 8 wells were used.
Uninfected control-HFF received 200 μl of full
medium, all other monolayers were infected with
100 μl of fullmediumcontaining2×103 freshlypuriﬁ-
ed T. gondii β-gal tachyzoites as above. After 1 h,
drug- and solvent-control samples were added, and
plates were incubated for 72 h at 37 °C/5% CO2. In
some experiments, DB750 or DB745 (1 μM) were
added already prior to infection, either to the host
cells or to the parasites, as indicated below. Subse-
quently, plates were centrifuged at 80 g for 5 min at
20 °C, the medium was removed, and wells were
washed once with 200 μl of PBS and centrifuged
again. Each well received 90 μl of PBS containing
0·05% Triton-X-100 and 10 μl of the enzyme sub-
strate (5 mM chlorophenylred-β-galactoside in PBS),
and the absorption was read at various time-points.
As determined by McFadden et al. (1997), the initial
velocity (ΔA570/min) was proportional to the num-
ber of tachyzoites down to 50 per well.
Determination of IC50 values
IC50 values of selected compounds (see Table 1) were
determined in cultures treated for 72 h with drugs at
diﬀerent concentrations ranging from 0 to 2 μM. IC50
values were calculated after the logit-log-transforma-
tion of the relative growth (RG; control=1) accord-
ing to the formula ln[(RG/(1-RG)]=a×ln(drug
concentration)+b and subsequent regression analysis
by the corresponding software tool contained in the
Excel software package (Microsoft, Seattle, WA,
USA).
Assessment of host cell toxicity
HFF were seeded into 24-well tissue-culture plates
and were grown to conﬂuency.Mediumwas removed
and 2ml containing the compounds of interest
(DB702, DB745, DB1127 and DB1282) were added
at concentrations between 0·5, 1, 2, and 3 μM. Con-
trols received corresponding amounts of DMSO-
solvent. After 3 days of culture, the medium was
replaced with fresh medium containing the same
amounts of the drugs, and culture was repeated for
another 3 days. Monolayers were inspected micro-
scopically on a daily basis and, at day 6, cell death was
Table 1. IC50 determination of selected compounds against diﬀerent Toxoplasma gondii strains, and
assessment of HFF toxicity
(IC50 s are given in μM+/−S.D. Three strains were evaluated: T.g. β-gal is a transgenic strain (Rh-background) that
expresses β-galactosidase constitutively. T.g. Me49 is a cyst-forming strain, T.g._DB750 was generated by culture of T.g.
Me49 in the presence of 1·2 μM DB750. (–) indicates not tested.)
Compound-
name
IC50 (μM) T.g. β-gal
colorimetric assay
IC50 (μM) T.g. Me49
qPCR
IC50 (μM) T.g._DB750
qPCR
HFF toxicity (μM) light
microscopy
DB750 0·11+/−0·006** 0·13+/−0·021** 0·48+/−0·03 >2*
DB745 0·03+/−0·002 0·03+/−0·016 0·07+/−0·08 >2*
DB702 0·15+/−0·007 (—) (—) >1*
DB1282 0·23+/−0·016 (—) (—) >0·5*
DB1127 (—) (—) (—) <0·5*
* Values are given for exposure of HFF to drugs for 2×3 days at 37 °C, 5% CO2, and induction of 50% or greater cell death.
** Values are in a similar range to that previously determined for T. gondii Rh (0·16 μM) by real time PCR (Leepin et al.
2008).
210Christian Kropf and others
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182011001776
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 21:09:15, subject to the Cambridge Core terms of use, available at
assessed by trypsinization, staining of cells with
Trypan blue, and counting the live and the dead
cells in a Neubauer chamber.
Determination of the eﬀects of DB745 treatment on
extracellular T. gondii β-gal
T. gondii β-gal tachyzoites (2×105 parasites in 1ml)
were re-suspended in pre-warmed (37 °C) or pre-
cooled (4 °C) full medium, and were incubated at the
respective temperature for 30min. Subsequently,
tubes were complemented with 1 μM DB745, or the
respective concentration of solvent (DMSO), and
were further incubated for either 2 h or 4 h at 4 °C and
37 °C, respectively. Subsequently, the tachyzoites
were centrifuged at 300 g for 10min at 4 °C, and were
re-suspended in 1ml of full medium. Then 100 μl of
the suspension was used per well of a 96-well plate to
infect a HFF monolayer grown to conﬂuency, and 8
wells were used for 1 experimental assay. The 96-well
plates were placed at 37 °C in 5% CO2 for 72 h.
Assessment of tachyzoite numbers was done by dete-
ction of β-galactosidase activity as described above
(McFadden et al. 1997; Müller et al. 2009).
In vitro adaptation of T. gondii Me49 to increased
concentrations of DB750 and DB745
Conﬂuent HFF monolayers were infected with
T. gondii Me49 in small tissue-culture ﬂasks and
were exposed to a stepwise increase in drug concen-
tration over time, starting with 0·05 μM for DB750
and 0·02 μM for DB745. The drug concentration was
elevated stepwise every 3–4 days by 0·05 and 0·02 μM,
respectively, with daily evaluation by light micro-
scopy. The drugs reached maximum concentrations
of 1·2 μM for DB750 and 0·46 μM for DB745. Every
6–9 days, parasites were passaged onto fresh HFF
by trypsinization of infected cultures, washing them
in PBS, and adding them to fresh monolayers
previously grown overnight. For both compounds a
further increase in drug concentration had to be
terminated due to host cell toxicity as judged by
microscopical assessment.
Proliferation of non-adaptedT. gondii tachyzoites and
DB750-adapted T. gondii_DB750 in the presence
and absence of DB750
Conﬂuent HFFmonolayers, grown in 24-well tissue-
culture plates, were infected with 103 freshly puriﬁed
non-adapted T. gondii or DB750-adapted T. gondii_
DB750 in full medium for 1 h at 37 °C/5% CO2.
Subsequently wells receivedDB750 to a ﬁnal concen-
tration of 1·2 μM, or the appropriate amount of
solvent (DMSO) alone, and were further incubated
at 37 °C/5%CO2 . Sample collection was done at 12 h,
36 h, 60 h, 84 h, 108 h, 134 h and 158 h following
initiation of drug treatment. For this, the super-
natants were removed, wells were trypsinized, and
cells were collected by centrifugation at 340 g for
10min at 4 °C. DNA was puriﬁed and samples were
processed for quantitative real-time PCR, both as
described above.
Diﬀerential immunoﬂuorescence staining of
extracellular and intracellular T. gondii
Me49 tachyzoites
The protocol previously applied for N. caninum
(Hemphill et al. 1996; Naguleswaran et al. 2003) was
used. In short, non-adapted T. gondii Me49 and
T. gondii_DB750 were resuspended in full medium
to 5×107 parasites/ml. Parasites were treated or not
with 1 μM DB745 for 1 h at 37 °C. Subsequently,
100 μl of parasite suspensions were allowed to settle
onto HFF cell monolayers grown on poly-L-lysine
(100 μg/ml) coated glass coverslips in 24-well tissue-
culture plates at 37 °C and 5% CO2 for 40min. Sub-
sequently, coverslips were rinsed in PBS and were
placed into ﬁxation buﬀer containing PBS/3% para-
formaldehyde/0·05% glutaraldehyde for 10min at
22 °C. The coverslips were washed extensively in
PBS and were incubated in PBS containing 1%
bovine serum albumin (BSA) and 50mM glycine
(blocking buﬀer) for 30min. The ﬁrst antibody layer
(polyclonal rabbit anti-T. gondii antiserum;
Scheidegger et al. 2005) was applied at a dilution of
1:500 in blocking buﬀer for 25min, followed by 3
washes in PBS, and the secondary antibody (goat
anti-rabbit-Texas red (Becton Dickinson Immuno-
cytometry Systems)) at a 1:200 dilution for 25min.
Afterwashing inPBS (3 times×5min), cellswereper-
meabilized by placing the coverslips into pre-cooled
methanol and acetone (×20 °C) for 5min each. After
rehydration in PBS, coverslips were placed into
blocking buﬀer, and were labelled with the same
polyclonal rabbit anti-Toxoplasma gondii antiserum
(1:500), and with a goat anti-rabbit-FITC (Becton
Dickinson Immunocytometry System) at a 1:200
dilution. Specimens were then washed extensively
(1 min in 2×concentrated PBS for 1min, followed
by additional rinses 5×5min in PBS). Finally,
coverslips were mounted onto glass slides using
Vectashield mounting medium containing DAPI
(Vector Laboratories, Burlingame, USA). Results
were obtained by inspection of 20 randomized chosen
ﬁelds (with at least 15 host cells) at 40 times
magniﬁcation on a Nikon ECLIPSE 80i ﬂuor-
escence microscope using all 3 channels. By counting
the FITC-labelled parasites the overall number of
T. gondii tachyzoites was determined. The number
of parasites located on the surface of the HFF cells
was determined by counting the Texas red immuno-
labelled tachyzoites. Finally, the number of intra-
cellular parasites was calculated.
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Transmission electron microscopy (TEM)
HFF monolayers grown in 25 cm2 tissue-culture
ﬂasks were infected with T. gondii Me49 or with
T.gondii_DB750. At 2 days post-infection, treatment
with DB750 or DB745 were initiated, both at 1 μM.
Samples were collected 24 h later, by removing the
medium, washing the monolayers twice with 100mM
sodium cacodylate buﬀer (pH 7·2), and ﬁxation in
100mM sodium cacodylate buﬀer, pH 7·3, containing
2·5% glutaraldehyde for 2 h. Then specimens were
washed twice with 100mM cacodylate buﬀer, scraped
oﬀ with a rubber policeman, and centrifuged at
100 g for 10min at 4 °C. Post-ﬁxation was done
in cacodylate buﬀer containing 2% OsO4 at 22 °C.
Subsequently, specimens were washed in water pre-
stained in 1% uranyl acetate in water for 30min,
followed by an extensive wash with water. The
samples were dehydrated in a graded series of ethanol
(30, 50, 70, 90, and 100%), and were embedded in
Epon 820 epoxy resin as described by Leepin et al.
(2008). The resin was polymerized at 65 °C for 24 h.
Ultrathin sections (*80 nm) were cut on a Reichert
and Jung ultramicrotome and were loaded onto
300-mesh copper grids (Plano GmbH, Marburg,
Germany), and stained with uranyl acetate and lead
citrate (Hemphill et al. 2004). Grids were viewed on a
Philips 400 transmission electron microscope (TEM)
operating at 80 kV.
RESULTS
In vitro activity of DB750 against T. gondii Rh
and T. gondii Me49
As determined by real time PCR quantiﬁcation,
DB750 was previously shown to be active against
T. gondii Rh (Rh-strain) tachyzoites, with an IC50 of
0·16 μM (Leepin et al. 2008). In order to investigate
whether T. gondii Me49 (Me49-strain) tachyzoites
exhibit a similar susceptibility, infected HFF mono-
layers were subjected to increasing concentrations of
DB750 (0–2 μM) for a period of 72 h. Real time PCR
showed that DB750 inhibited growth of T. gondii
Me49with an IC50 of 0·13 μM, which was in the same
range, as previously reported for T. gondii Rh
tachyzoites (Leepin et al. 2008).
To further characterize the eﬀects of DB750 in
T. gondii tachyzoites, and to facilitate screening for
other potentially interesting compounds in a more
cost-eﬀective manner, a T. gondii transgenic strain
(T. gondii β-gal; Rh-background) was employed that
constitutively expressed β-galactosidase (McFadden
et al. 1997).DB750 inhibited proliferation ofT. gondii
β-gal with an IC50 of 0·11 μM (see Table 1). Thus,
T. gondii Rh, T. gondii β-gal, and T. gondii Me49
exhibited similar susceptibility to the action of
DB750.
Further investigations were carried out employing
T. gondii β-gal (Fig. 1). As expected, culture of
T. gondii β-gal tachyzoites in HFF for 72 h in the
presence of 1 μM DB750 did not result in tachyzoite
proliferation, regardless of whether the drug was
added 1 h after infection or during the invasion
phase (see Fig. 1A, B). As previously observed for
N. caninum (Leepin et al. 2008), incubation of un-
infected HFF monolayers with 1 μM DB750 for 12 h
prior to infection, and subsequent infection with
T. gondii tachyzoites and culture for 72 h, also did not
result in any parasite growth (see Fig. 1C). In order to
investigate whether the activity of DB750 was main-
tained in the supernatant of HFF monolayers after
12 h of treatment, freshly puriﬁed T. gondii tachy-
zoites were suspended in the medium supernatant
originating from HFF cultures treated for 12 h, and
were used for infection and culture on fresh HFF
monolayers for 72 h. T. gondii tachyzoites readily
proliferated in that pre-used medium (Fig. 1D).
T. gondii tachyzoites can readily adapt to the eﬀects
of DB750 treatment in vitro
In order to establish whether T. gondii tachyzoites
would be able to adapt, or possibly acquire resistance,
to DB750, we cultured T. gondii Me49 tachyzoites in
HFF monolayers, by increasing the drug concen-
tration stepwise every 2–3 days, starting at 0·05 μM
and ending at 1·2 μM. Upon exposure to concen-
trations of more than 1·2 μM DB750 for more than
10 days, HFF monolayers exhibited aberrant mor-
phological alterations, which indicated toxic eﬀects
upon longer-term exposure (data not shown). Never-
theless, a DB750-adapted T. gondii strain with Me49
background (T. gondii_DB750) was generated which
still readily proliferated at 1·2 μM drug concentration.
The ability of T. gondii_DB750 to resist elevated
drug concentrations was retained after freezing of
Fig. 1. Eﬀects of DB750 against Toxoplasma gondii β-gal
employing 72 h in vitro-growth assays. (A) T. gondii
tachyzoites were allowed to infect HFF monolayers and
1 μM DB750 was added 1 h later. (B) DB750 was added
already during the invasion phase. (C) HFF monolayers
were cultured for 12 h in medium containing 1 μM
DB750, washed extensively with medium, and freshly
isolated T. gondii tachyzoites were added subsequently.
(D) Freshly puriﬁed T. gondii tachyzoites were re-
suspended in the medium supernatant obtained from (C)
and added to HFF monolayers. Note the inhibition of
parasite growth in (A), (B) and (C), and extensive parasite
proliferation in (D). Shown is 1 of 3 experiments with
essentially identical outcome.
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infected cells in liquid nitrogen using a medium
composed of FCS/10%DMSO, short-term storage in
liquid nitrogen, and subsequent thawing and culture
in DB750-containing medium. The proliferation
of T. gondii_DB750 in the presence of diﬀerent con-
centrations (0–2 μM) of DB750 was assessed in 72 h-
growth assays in HFF, and yielded an IC50 of
0·48 μM, which was almost 4 times higher than that
for the non-adapted strain (0·13 μM; see Table 1).
Subsequently, the proliferation-kinetics of non-
adapted T. gondii Me49 and T. gondii-DB750 within
a time frame of 156 h were comparatively assessed by
real time PCR in the presence and absence of 1·2 μM
DB750, respectively (Fig. 2). Within the ﬁrst 84 h of
culture in the absence and presence of DB750 both
T. gondii strains exhibited similar growth kinetics.
Subsequently, in the absence of DB750, the non-
adapted T. gondii Me49 tachyzoites proliferated at
a signiﬁcantly higher rate (P<0·05) compared to
T. gondii_DB750, until the time-point 156 h post-
infection, at which the numbers of T. gondii_DB750
increased dramatically (Fig. 2A). In the presence of
1·2 μM DB750 (Fig. 2B), the DB750-adapted strain
was proliferating slightly more rapidly from 84 h
post-infection onwards until the end of the assay.
However, surprisingly, a substantial proliferation of
non-adapted T. gondii Me49 tachyzoites could be
observed from 84 h post-infection onwards, and the
parasite numbers of the two strains were not signiﬁ-
cantly diﬀerent at any time-point. Thus, DB750 did
not exhibit parasiticidal activity against non-adapted
T. gondii Me49 tachyzoites when applied at high
(1·2 μM) concentration. Conversely, T. gondii Me49
tachyzoites rapidly adapted to the action of the
compound within the short time frame of 5–6 days
of treatment. The same potential to readily adapt to
DB750 treatment was observed for T. gondii β-gal
tachyzoites (data not shown).
In vitro screening of di-cationic pentamidine
derivatives against T. gondii tachyzoites leads to
the identiﬁcation of DB745
T. gondii β-gal tachyzoites were used for the screen-
ing of a series of selected di-cationic pentamidine
derivatives, including 10 di-arylimidamides (DB666,
DB667, DB702, DB710, DB745, DB780, DB786,
DB865, DB891, or DB930), 6 diamidines (DB1282,
DB1341, DB1362, DB1407, DB1450 or DB1479),
15 newly generated mono-arylimidamides (DB1980,
DB1996, DB1997, DB2001, DB2002, DB2006,
DB2007, DB2018, DB2036, DB2045, DB2048,
DB2074, DB2079, DB2081, or DB2083), and the
di-guanidino analogue DB1127, all at an initial con-
centration of 1 μM. Evaluation of β-galactosidase
activity after 72 h of exposure to these drugs revealed
that the mono-arylimidamides tested did not show
any adverse eﬀects on T. gondii proliferation nor on
host cells, but proliferation-inhibitory eﬀects were
imposed by the di-arylimidamides DB702 and
DB745, the di-guanidino-analogue DB1127, and
the di-amidine DB1282 (see Table 1).
Assessment of host cell toxicity by light micro-
scopical inspection of uninfected HFF monolayers
exposed to increasing concentrations of the drugs
(0, 0·5, 1, 2 or 3 μM) twice/day for 3 days revealed that
DB1282 induced over 50% cell death already at 1 μM,
and DB1127 lead to 80% HFF death at a concen-
tration of 0·5 μM. Fifty % of viable HFF compared
to untreated samples were found in cultures treated
with 2 μM DB702 (Table 1). For DB745, treatments
with 0·5–2 μM did not result in adverse reactions
in HFFmonolayers, while at 3 μM a 50% reduction in
viable HFF was observed. Thus, DB745, with an
IC50 for T. gondii β-gal of 0·03 μM, and favourable
selective toxicity was selected for further study
(see Table 1).
Fig. 2. Proliferation kinetics of Toxoplasma gondii Me49 and DB750-adapted T. gondii_DB750 in HFF monolayers. (A)
Growth curves in the absence of DB750 and (B) in the presence of 1·2 μM DB750. Parasite quantiﬁcation was performed
by quantitative real time PCR at diﬀerent time-points as indicated in the x-axis over a period of 156 h. Shown is 1 of 2
experiments with essentially identical outcome. P values <0·05 indicate signiﬁcant diﬀerences in parasite numbers of the
two strains when cultured in the absence of DB750.
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Characterization of the eﬀects of DB745 on
proliferation and host cell invasion of non-adapted
(T. gondii Me49) and DB750-adapted
(T. gondii_DB750) tachyzoites
DB750 and DB745 exhibit a similar molecular
structure (Fig. 3A). They diﬀer in molecular weight
(590·46 and 655·60, respectively), and in contrast to
DB750, DB745 possesses an ethyl-moiety on each of
the 1′-positions of the aryl rings. The proliferation of
non-adapted T. gondii Me49 and T. gondii_DB750 in
the presence of 1 μM DB745 was assessed in 72 h
growth-assays, and compared with T. gondii_DB750
tachyzoites treated with 1·2 μM DB750 (Fig. 3B). As
expected, DB745 completely blocked the prolifer-
ation of non-adapted T. gondii Me49 tachyzoites
(IC50=0·03 μM; see Table 1). The DB750-adapted
T. gondii_DB750 tachyzoites readily underwent
proliferation in the presence of 1·2 μM DB750
(IC50=0·48 μM; see Table 1), but were signiﬁcantly
impaired in the presence of DB745 (IC50 of 0·07 μM;
see Table 1). However, the inhibition of proliferation
was signiﬁcantly less pronounced as for non-adapted
T. gondii Me49.
In order to investigate whether DB745 also had
an impact on extracellular T. gondii tachyzoites,
T. gondii β-gal tachyzoites were separated from their
host cells and exposed to DB745 (1 μM) for periods of
2 h and 4 h, either at 4 °C or at 37 °C (Fig. 4A).
Subsequently, the drugs were removed, and parasites
were added to HFF monolayers, and proliferation of
tachyzoites was assessed after 72 h. Upon incubation
of isolated tachyzoites at 4 °C, DB745 already had a
profound impact on the infectivity of the parasites,
yieldinga reductionof tachyzoitenumbers of approxi-
mately 60% after both 2 and 4 h exposure-time to the
drug. At 37 °C, the impact of DB745 on parasite
infectivity was even more pronounced, yielding a
reduction in parasite numbers of 80% after 2 h, and
over 90% upon 4 h of extracellular exposure toDB745
(Fig. 4A). This suggested that DB745 impaired the
viability of extracellular parasites in a time- and
temperature-dependent manner.
The eﬀect of DB745 on host cell invasion was
assessed using T. gondii Me49 and employing
immunoﬂuorescence microscopy and applying a
Fig. 4. Eﬀects of DB745 on the infectivity of
extracellular Toxoplasma gondii tachyzoites. (A) T. gondii
β-gal tachyzoites were incubated in the presence or
absence of 1 μM DB745 for 2 h or 4 h, either at 4 °C or at
37 °C. They were then used for infection and
proliferation in HFF monolayers for a period of 72 h
prior to quantiﬁcation of β-galactosidase activity. Results
in terms of parasite proliferation are presented as a
percentage in relation to treatments without drug (given
as 100% β-galactosidase activity). The assays were done in
quadruplicate. (B) Assessment of DB745-mediated
inhibition of invasion of T. gondii Me49 tachyzoites by
immunoﬂuorescent distinction of intracellular and
extracellular parasites. Results were obtained by
diﬀerential staining and subsequently counting the
parasites in 20 randomly chosen ﬁelds at 40 times
magniﬁcation. Extracellularly located parasites ﬂuoresce
with Texas-red and the overall number of parasites was
determined by FITC-staining. Note the reduction of
invasive parasites after incubation with 1 μM DB745 for
1 h. Shown are the results of 1 of 2 experiments with
essentially identical outcome.
Fig. 3. Properties of DB750 and DB745. (A) Structures
and molecular weights of DB750 and DB745. (B)
Proliferation inhibitory eﬀects of DB750 and DB745 over
a period of 72 h. Parasite quantiﬁcation was done by
quantitative real time PCR. In (B) the proliferation of
Toxoplasma gondii Me49 over a period of 72 h was
completely inhibited by the presence of 1 μM DB745
(left). T. gondii_DB750 proliferation was not inhibited by
the presence of 1·2 μM DB750 (middle), but signiﬁcantly
impaired by the presence of 1 μM DB745 (right). Shown
is 1 of 2 experiments with essentially identical outcome.
214Christian Kropf and others
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182011001776
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 21:09:15, subject to the Cambridge Core terms of use, available at
diﬀerential staining procedure that allowed distinc-
tion of intracellular and extracellular parasites
(Hemphill et al. 1996; Naguleswaran et al. 2003).
Following exposure of non-adapted T. gondii Me49
tachyzoites to 1 μM DB745 for 1 h, parasites were
washed and allowed to interact withHFFmonolayers
for 1 h (Fig. 4B). As a control, non-treated parasites
were subjected to the same procedure without com-
pound. Of 857 non-treated tachyzoites, 173 (20·2%)
were located within host cells. In contrast, in DB745-
treated samples the overall number of counted para-
sites was reduced to 664 tachyzoites and only 66
(11·2%) were found to be intracellular (Fig. 4B). No
such eﬀect was seen when T. gondii-DB750 tachy-
zoites were exposed to DB745 treatment, and when
non-adapted T. gondii Me49 tachyzoites were ex-
posed to DB750 (data not shown).
In vitro adaptation of T. gondii Me49 tachyzoites
to DB745
In order to explore the potential of T. gondii Me49
tachyzoites to adapt to DB745 treatment, the concen-
tration of the drug during the culture of infected
HFF monolayers, starting at 0·02 μM, was increased
stepwise by 0·02 μM every 3–4 days (see Table 2). As
for DB750, T. gondii Me49 tachyzoites exhibited an
astonishing capacity to also adapt to DB745, albeit at
a much slower speed, but ﬁnally still undergoing
proliferation up to a concentration of 0·46 μM. Rapid
adaptation to increasing concentrations of DB745 as
previously observed for DB750 was not possible. At
higher concentrations, exposure to DB745 during
periods of 10 days or longer lead to deterioration of
the HFF monolayers. Thus, besides exhibiting a
higher anti-parasitic activity compared to DB750,
DB745 also showed an increased host cell toxicity.
The IC50 of DB745 for this DB745-adapted strain
was not determined.
Eﬀects of DB745 on the ultrastructure of T. gondii
tachyzoites
Diﬀerences in eﬃcacy of DB745 against non-adapted
and DB750- adapted T. gondii_DB750 tachyzoites
were also detectable at the ultrastructural level. HFF
monolayers infected with T. gondii_DB750 or non-
adapted T. gondii were treated with 1 μM DB750 and
DB745, respectively, for 24 h, and were processed for
TEM (Figs 5 and 6). In non-adapted T. gondii Me49
both, DB750 (Fig. 5B) and DB745 (Fig. 5C, D)
induced severe morphological alterations in parasite
ultrastructure, as can be seen by, for example, the for-
mation of increased cytoplasmic vacuoles with mem-
branous and often granular content, the presence
of membrane stacks, and electron-dense inclusions.
In DB750-adapted T. gondii_DB750 tachyzoites
(Fig. 6) there were no obvious diﬀerences observed
in the ultrastructure of untreated (Fig. 6A) and
DB750-treated T. gondii_DB750 tachyzoites
(Fig. 6B), conﬁrming the complete adaptation of
these parasites to the drug. In contrast, populations
with diﬀerent degrees of structural alterations were
detected in cultures infected with T. gondii_DB750
tachyzoites and treated with DB745. In some
instances seemingly viable parasites with normal or
only slightly aberrant ultrastructural organization
(Fig. 6C and D) could be seen, often in the direct
vicinity of tachyzoites that exhibited extensive
cytoplasmic distortions such as increased vacuoliza-
tion and membranous inclusions (Fig. 6C, E). These
aberrant structural changes point towards severe
metabolic impairment of aﬀected tachyzoites. In ad-
dition, numerous non-viable tachyzoite-remnants
were detected in DB745-treated cultures (Fig. 6F).
Table 2. Schedule for the establishment of a
DB745-adapted Toxoplasma gondii Me49 line
(At indicated time-points the medium was replaced with
new medium containing either slightly elevated concen-
trations (+0·02 μM) of DB745, or (at the later time-points)
medium was changed with drug concentration unchanged
as indicated. Every 6–10 days cultures were trypsinized and
seeded onto fresh HFF monolayers. At day 111 and a
DB745 concentration of 0·46 μM, host cell monolayers
exhibited clear signs of disintegration and the adaptation
process was stopped.)
Time-points of
treatment (days) DB745 (μM)
0 0·02
3 0·02
7 0·04
10 0·06
14 0·08
17 0·10
21 0·12
24 0·14
27 0·14
31 0·16
35 0·18
38 0·20
42 0·22
45 0·24
48 0·26
52 0·28
56 0·30
59 0·32
63 0·34
66 0·36
69 0·38
73 0·40
76 0·40
80 0·40
83 0·42
86 0·42
90 0·42
93 0·42
97 0·42
101 0·42
104 0·42
108 0·44
111 0·46
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DISCUSSION
Although pentamidine was synthesized already in the
1930s, it has remained the only aromatic diamidine
that is widely used in the clinic, especially against
human stage 1 African trypanosomiasis caused by
Trypanosoma brucei gambiense, but also against Pneu-
mocystis pneumonia caused by Pneumocystis jiroveci,
and against leishmaniasis, and Candida albicans
infections (Werbovetz, 2006). A number of arylimi-
damides, including DB702, DB750, DB766, DB786,
DB811 and DB889 exhibited good in vitro activity
against Trypanosoma cruzi, N. caninum, B. besnoiti
or L. donovani (Stephens et al. 2003; Silva et al.
2007a, b; Leepin et al. 2008; Cortes et al. 2011), and
DB766 eﬀectively reduced the parasite burden in the
blood and heart of T. cruzi-infected mice at a dose of
100mg/kg/day given orally and intraperitoneally
(Batista et al. 2010a). Thus, the goal of this inves-
tigation was to study the interactions of T. gondii
tachyzoites with DB750, which had shown interest-
ing properties in a previous study (Leepin et al.
2008), and possibly identify other compounds with
good in vitro activity. This included eﬀects of these
compounds on intracellular proliferation, host cell
toxicity, parasiticidal activity, the involvement of the
host cells in drug activity, and the potential of these
parasites to adapt to the adverse conditions during
in vitro drug treatment.
The di-cationic molecules used here have been
designed to have improved pharmacokinetic proper-
ties by including aryl groups on one of the amidine
nitrogen atoms (Wang et al. 2010) and DB750 was
an obvious drug candidate due to its low IC50 against
T.gondiiRh (0·23 μM), and lowtoxicity inHFFmono-
layers (Leepin et al. 2008). Previous studies had also
shown that the HFF host cells actually participated
in the activity against closely related N. caninum
tachyzoites, most likely by taking up the drug and
providing the host cell with a ‘memory eﬀect’, thus
exerting the anti-parasitic activity against intracellu-
lar tachyzoites even in the absence of added drug
(Leepin et al. 2008). However, DB750 did not aﬀect
the viability and invasive capacities of extracellular
N. caninum and T. gondii Rh tachyzoites (Leepin
et al. 2008). Moreover, recent in vivo studies in mice
Fig. 5. TEM of the eﬀects of DB750 and DB745 (1 μM, 24 h) against Toxoplasma gondii Me49 tachyzoites cultured in
HFF. (A) Control without drug treatment, with T. gondii Me49 tachyzoites surrounded by a parasitophorous vacuole
membrane (pvm) and exhibiting cytoplasmic organelles such as nucleus (nu), rhoptries (rop) and dense granules (dg).
Scale bar=0·7 μm. (B) T. gondii Me49 tachyzoites incubated in the presence of DB750, exhibiting extensive
vacuolization, and substantial degradation of the cytoplasmic architecture (v). Scale bar=0·9 μm. (C) Shows a group of
T. gondii Me49 tachyzoites incubated in the presence of DB745 (Scale bar=0·9 μm), and (D) displays a higher
magniﬁcation view of the parasite indicated by the large arrow (Scale bar=0·4 μm). In (D), note the presence of
cytoplasmic vacuoles, either seemingly empty or ﬁlled with a meshwork of ﬁlamentous and granular material of
unknown origin (v) and the large stacks of membrane adjacent to the nucleus (nu). In all drug-treated samples,
the pvm appeared still largely intact and clearly discernible.
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experimentally infected with the N. caninum tachy-
zoites showed that DB750-treatment, applied intra-
peritoneally at 2 mg/kg/day for a period of 14 days,
had a beneﬁtial impact by reducing clinical signs of
neosporosis and diminishing the cerebral parasite
load (Debache et al. 2011). Thus, we attempted to
characterize the eﬀects mediated by DB750 in 2
diﬀerent strains of T. gondii, Rh and Me49, which
represent strains of high and low virulence in mice,
respectively (Dardé, 2008).
By employing 72 h-growth assays, DB750 IC50
values for the two Toxoplasma strains, T. gondii β-gal
(Rh background) and T. gondii Me49, were shown to
be in the similar low range (0·11–0·16 μM) of the
previously reported IC50 for T. gondii Rh (Leepin
et al. 2008). Thus, the assessments of parasite
proliferation by a colourimetric assay based on the
quantiﬁcation of β-galactosidase activity (McFadden
et al. 1997) and the quantiﬁcation of parasite numbers
by quantitative real time PCR produced similar
results.
Similar to what was previously reported for
N. caninum,DB750 retained its anti-parasitic activity
againstT. gondii also upon pre-treatment of host cells
Fig. 6. TEM of the eﬀects of DB750 and DB745 (1 μM, 24 h) against DB750-adapted Toxoplasma gondii-DB750
tachyzoites cultured in HFF. (A) Control, displaying T. gondii_DB750 tachyzoites without drug treatment. Typical
components such as the parasitophorous vacuole membrane (pvm), rhoptries (rop), dense granules (dg) and micronemes
(mic) at the apical pole of the tachyzoites are clearly discernible. The arrow points towards the conoid. Scale bar=1 μm.
(B) T. gondii_DB750 tachyzoites incubated in the presence of DB750. Note that these parasites seem largely unaﬀected
by the drug treatment. (C–F) T. gondii_DB750 cultured in the presence of DB745; in (C) tachyzoites exhibiting only
moderate alterations and still exhibiting a largely intact cytoplasmic organization (vertical arrow), and another tachyzoite
with increased vacuole formation (horizontal arrow) are shown. (D) Higher magniﬁcation view of (C). Scale bars in
(C)=0·9 μm, in (D)=0·4 μm. (E) and (F) Show tachyzoites that exhibit more severe alterations due to drug treatment
such as intracytoplasmic vacuoles (v), lipid droplet formation (ld) and a general desintegration of the cellular
architecture. Scale bars in (E) and (F)=0·5 μm. In all drug-treated samples, the pvm appeared still intact and clearly
discernible.
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for prior to infection and subsequent culture for 72 h
in the absence of the drug. In addition, no anti-
parasitic activity could be seen in the corresponding
HFF-medium supernatant. The lack of DB750-
activity in medium supernatant after 12 h of incu-
bationwithHFF could be potentially explained (i) by
metabolic degradation of DB750 or (ii) by highly
eﬃcient drug-uptake by the host cells. The fact that
the anti-parasitic eﬀect was retained in these pre-
treated HFF cells but was no longer evident in the
corresponding medium supernatant supports the
notion of DB750 being actively taken up by HFF
monolayers and subsequently retained in the host cell
cytoplasm.How this is achieved is not known; passive
and active transport could be involved. Ming et al.
(2008) identiﬁed a human organic cation transporter
for which pentamidine and furamidine act as sub-
strates, and possibly such transporters could mediate
DB750 uptake into HFF. In addition, intracellular
accumulation of DB750 within the HFF monolayers
could be responsible for the toxicity that was detected
upon culture of infected ﬁbroblasts for more than
10 days in the presence of DB750 at concentrations
higher than 1·2 μM.
Although the promising IC50 values achieved in
72 h assays indicated that T. gondii tachyzoites were
highly susceptible to DB750 treatments, it became
clear that these parasites exhibited a surprising ability
to rapidly adapt to approximately 10 times higher
drug concentrations within 5–6 days following initia-
tion of treatment. The resulting DB750-adapted
T. gondii strain, T. gondii_DB750, had an IC50 of
0·48 μM and could still undergo proliferation in HFF
at a drug concentration of 1·2 μM. In comparison to
T. gondii, the closely related N. caninum (Nc-1 and
Nc-Liv isolates) did not exhibit the ability to rapidly
adapt to such high concentrations of DB750. DB750
adaptation of Neospora populations could only be
achieved after several weeks of careful and stepwise
increase of drug concentrations up to 0·2–0·3 μM.
Thus, although phylogenetically closely related, the
two species seem to exhibit a diﬀerent adaptation
proﬁle.Most likely,T. gondii has amore sophisticated
metabolic machinery to deal with adverse life con-
ditions, and it would be interesting to investigate
the molecular mechanisms involved. In any case, the
lower potential ofNeospora to react to environmental
changes could be a determining factor that limits
the range of potential intermediate hosts of this para-
site in comparison to T. gondii (Hemphill et al. 2006;
Dubey et al. 2007).Thus, a higher degree ofﬂexibility
on the transcriptional and translational level (re-
viewed by Bougdour et al. 2010) may have enabled
T. gondii tachyzoites to adapt to the arylimidamide
compound DB750 within this short time span.
By monitoring the growth of T. gondii Me49 and
T.gondii_DB750 in the presence of DB750 over
time, the capacity of T. gondii_DB750 to proliferate
at a slightly higher rate compared to non-adapted
parasites was demonstrated. However, the fact that
T. gondii Me49 tachyzoites were able to adapt to
1·2 μM DB750 and resume proliferation in such a
short time frame was surprising. Adaptation could be
accompanied by an increased expression of genes
coding for components of the Toxoplasma detoxiﬁca-
tion machinery, such as e.g. ATP-binding cassette
(ABC) transporters, which represent an important
family of membrane proteins involved in drug re-
sistance and other biological activities (Sauvage
et al. 2009). A prominent ABC transporter, P-
glycoprotein (TgABC.B1 and TgABC.B2) poten-
tially mediating transport of the drug out of the cell,
are associated with the membrane in tachyzoites, and
is constitutively expressed in all 3 virulent types. On
the other hand, another adaptation mechanism could
involve the reduced uptake of drug, due to the down-
regulation of certain adenosine transporter activities,
which are involved in diamidine uptake (Matovu
et al. 2003; Witola et al. 2004). For instance, homo-
logues to the P2 aminopurine transporter in T. brucei
are found in the Toxoplasma genome (www.toxodb.
org). This protein normally transports essential
adenosine and adenine, but is also responsible for
the eﬃcient transfer of pentamidine and the diami-
dine DB75 into the trypanosome interior (Lanteri
et al. 2006). Down regulation of the expression of
suchadenosinetransporterswouldthen,besides limit-
ing diamidine uptake, also limit the uptake of other
essential molecules such as aminopurines, which are
important for proliferation. This could explain the
initial reduced proliferation of T. gondii_DB750
compared toT. gondiiMe49 in the absence of DB750.
Evidently, these ﬁndings on DB750 did not allow
high expectations in terms of a potential in vivo
eﬃcacy of DB750 against T. gondii infection. As a
consequence, we aimed to search for additional active
di-cationic compounds with increased anti-parasitic
activity, leading to the identiﬁcation of DB745.
DB750 and DB745 exhibit a highly similar mol-
ecular structure. However, the change of the hydro-
xyl groups on the benzene ring to ether-coupled ethyl
groups could have providedDB745 with an increased
metabolic resistance and membrane permeability,
since the compound is slightly more lipophilic (log P
at pH 7·4=3·82; Wang et al. 2010), which could in
turn increase the chances of the drug passing several
layers of membrane, including the host cell plasma
membrane,parasitophorousvacuolemembrane,para-
site membrane, and the membrane of a potential
target organelle. Which target is actually aﬀected by
DB745 is not clariﬁed to date. Current evidence
suggests that aromatic diamidines bind to AT-rich
sites in the DNA minor groove, and thus inhibit
transcription or the interaction with DNA-binding
enzymes such as topoisomerases or nucleases
(Wilson et al. 2008). This indicates that these com-
pounds could inﬂuence gene expression, and thus
many diverse cellular functions could be aﬀected.
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In kinetoplastids, ﬂuorescence microscopy had
demonstrated that these drugs associate with the
kinetoplast DNA, which is in agreement with the
observed mitochondrial swelling seen in T. cruzi
upon incubation with diamidines (Batista et al.
2010b). However, neither DB750 nor DB745 exhibit
ﬂuorescent properties, thus it was not possible to
localize these drugs, neither within the host cells nor
within the parasites.
DB745 did not only aﬀect the proliferation of
intracellular T. gondii tachyzoites, but also exhibited
pronounced eﬀects upon treatment of extracellular
parasites. This showed that, in order to be active
DB745 is not required to be metabolized by the host
cell. In contrast, DB750 did not aﬀect the viability of
extracellularN. caninum andT. gondii Rh tachyzoites
(Leepin et al. 2008) nor did it have an impact on the
invasive properties of T. gondii Me49 tachyzoites.
Thus, the decrease in the IC50 (from0·13 μM (DB750)
to 0·03 μM (DB745)) against T. gondii Me49 could be
due to an added eﬀect such as the impairment of
extracellular parasites. As a consequence, T. gondii
Me49 adaptation to the eﬀects of DB745 treatment
took place much less eﬃciently and only after ex-
tended periods of time. Rapid adaptation to DB745,
as seen for DB750, was not possible.
The impact of pre-treatments on the viability of
T. gondii Me49 tachyzoites with DB745 at 37 °C was
time dependent, and these eﬀects were less pro-
nounced upon pre-treatment at 4 °C and, at lower
temperature, time independent. By employing an
adhesion/invasion assay that allowed distinction be-
tween adhering tachyzoites and intracellular tachy-
zoites, the negative impact of DB745-treatments
of extracellular tachyzoites was conﬁrmed micro-
scopically. The fact that the IC50 of DB745 for
T. gondii_DB750 was about 2 times higher compared
to the IC50 for T. gondii Me49 (0·07 μM versus
0·03 μM) can be explained by the similarities in
structure of DB750 and DB745, thus adaptation to
DB750 must have had some cross-protective eﬀect.
HFF monolayers infected with T. gondii Me 49 and
T. gondii_DB750 were exposed to either DB750 or
DB745, both at 1 μM for 24 h, and the eﬀects were
monitored by TEM. As expected, DB750 did not
aﬀect T. gondii_DB750, while DB745 clearly had a
much higher impact. However, seemingly structu-
rally unharmed parasites were occasionally visible.
This indicates and conﬁrms that a certain degree of
cross-adaptation had taken place in some tachyzoites,
but not in all. This also clearly shows that DB745,
although highly eﬀective in 3 day-growth assays, does
not readily kill all parasites, even at high concen-
trations, allowing adaptation to take place in some
tachyzoites.
In conclusion, we have demonstrated an astonish-
ing ability of the apicomplexan parasite T. gondii to
adapt to the eﬀects of the arylimidamide DB750
within a time span of 5–6 days in culture. DB750 had
previously provided encouraging data on selective
anti-Toxoplasma eﬃcacy in vitro. Thus our ﬁndings
question the value of short-term (e.g. 72 h) in vitro
assays for the evaluation of anti-Toxoplasma proper-
ties, and corresponding investigations that include
longer-term in vitro drug exposure could provide
more reliable results. T. gondii could also adapt to
(less) elevated levels of DB745, although only after
many weeks in cell culture. Drug adaptation is also
likely to happen in vivo, since chemotherapeutical
treatment failures when employing pyrimethamine,
sulfadiazine and clindamycine have been reported
frequently (Dedicoat and Livesley, 2006; Ribera
Pasquet et al. 1998). Clearly, Toxoplasma represents
a true survival artist, and this illustrates the inherent
diﬃculties in obtaining reliable and eﬃcacious drugs
for the treatment of toxoplasmosis. Arylimidamides,
however, represent a class of compounds that could
serve this cause. DB745 should be followed up in an
appropriate in vivo model, and the molecular
mechanisms of the outstanding adaptive potential of
T. gondii must be elucidated in future studies.
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